Generally, Health Economic Evaluation is an accepted method to evaluate the economic consequences of medical interventions. Thus, Health Economic Evaluation identifies the costs (the consumption of resources), as well as the clinical, economic and human consequences of therapies.
For pharmaceutical companies profitability analysis represents a key challenge.
Pharmacoeconomics offers the possibility to conduct evaluations of therapies in the context of associated costs and medical consequences. To assure a methodological standard, the Institute for Pharmaeconomic Research (IPF) developed – in cooperation with important deputies of the health care system in Austria – Guidelines for Health Care Evaluation.
To show the value for money the reimbursement submission represents a key challenge for pharmaceutical companies. Health Economic Evaluation offers the possibility to conduct evaluations of therapies in the context of associated costs and medical consequences.
Pharmacoeconomic is thus an empirical, interdisciplinary science in the various therapeutic areas, being the interface between medicine, economics and statistics.
For the Institute for Pharmaeconomic Research (IPF), Health Economic Evaluation is one of the most important and largest contract areas with their subareas.
The IPF offers the following Portfolio within the area of Health Economic Evaluation:
Accordingly, we have recourse to a great wealth of experience.